Guoming Wu

Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II trial (ALTER0302)

Baohui Han, Kai Li, Yizhuo Zhao et al. · British Journal of Cancer · 2018 · 263 citations · Full text

Medicine, Oncology, Pharmacology +16

Two plasma microRNA panels for diagnosis and subtype discrimination of lung cancer

Shaohua Lu, Hui Kong, Yingyong Hou et al. · Lung Cancer · 2018 · 110 citations · Full text

Medicine, Molecular Medicine, Oncology +17

Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial

Li Li, Liyan Jiang, Yubo Wang et al. · Clinical Cancer Research · 2019 · 73 citations · Full text

Medicine, Oncology, Pharmacology +12

Probability of cancer in high‐risk patients predicted by the protein‐based lung cancer biomarker panel in China: <scp>LCBP</scp> study

Dawei Yang, Xiaoju Zhang, Charles A. Powell et al. · Cancer · 2017 · 55 citations · Full text

Medicine, Oncology, Cancer Screening +16

Association of Mitochondrial DNA Variations with Lung Cancer Risk in a Han Chinese Population from Southwestern China

Shizhen Zheng, Pin Qian, Fuxiang Li et al. · PLoS ONE · 2012 · 46 citations · Full text

Medicine, Genetics, Molecular Genetics +14